Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$103.14 USD

103.14
5,076,184

+0.18 (0.17%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $103.11 -0.03 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

GE HealthCare (GEHC) Unveils Head-Only MR Scanner SIGNA MAGNUS

by Zacks Equity Research

GE HealthCare's (GEHC) new SIGNA MAGNUS can delve deep into the brain's microstructure, microvasculature and function, providing researchers with a clearer picture of neurological diseases and disorders.

Zacks Equity Research

The Zacks Analyst Blog Highlights Alphabet, Netflix, Amazon, ServiceNow and Boston Scientific

by Zacks Equity Research

Alphabet, Netflix, Amazon, ServiceNow and Boston Scientific are included in this Analyst Blog.

Nalak Das headshot

A Golden Opportunity to Enter U.S. Stock Markets: 5 Top Picks

by Nalak Das

We have narrowed our search to five U.S. corporate behemoths that have strong growth potential for 2024. These are: GOOGL, NFLX, AMZN, NOW, BSX.

Zacks Equity Research

Avanos (AVNS) Q1 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Avanos' (AVNS) first-quarter results show strong bottom-line improvement along with decent growth in segmental revenues.

Zacks Equity Research

Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up

by Zacks Equity Research

Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.

Zacks Equity Research

Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up

by Zacks Equity Research

Hologic's (HOLX) GYN Surgical Q2 performance was driven by strong results from MyoSure and Fluent Fluid Management.

Zacks Equity Research

Lantheus (LNTH) Q1 Earnings Surpass Estimates, Gross Margin Up

by Zacks Equity Research

Lantheus' (LNTH) robust revenues from the majority of its segments drive its first-quarter performance.

Zacks Equity Research

DaVita (DVA) Q1 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

DaVita's (DVA) robust segmental revenues drive its first-quarter performance.

Zacks Equity Research

Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Decline

by Zacks Equity Research

Bruker's (BRKR) BioSpin segment witnessed growth across biopharma, academic government and industrial research in the first quarter of 2024.

Zacks Equity Research

Teleflex (TFX) Q1 Earnings Beat Estimates, Margins Rise

by Zacks Equity Research

Teleflex's (TFX) first-quarter 2024 results reflect growth across the majority of the company's product families in EMEA.

Zacks Equity Research

GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment

by Zacks Equity Research

GE Healthcare (GEHC) unveils Revolution RT, along with other upgrades, from its portfolio during the ESTRO 2024 Congress.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q1 Earnings In Line, Revenues Decline Y/Y

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) first-quarter 2024 results showcase a decline in year-over-year sales with an improved bottom line.

Zacks Equity Research

Zimmer Biomet (ZBH) Q1 Earnings Beat, Margins Expand

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER.

Zacks Equity Research

Envista (NVST) Q1 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Envista (NVST) registers a year-over-year decline in both segments in the first quarter of 2024.

Zacks Equity Research

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.

Zacks Equity Research

Cardinal Health (CAH) Beats on Q3 Earnings, Ups '24 EPS View

by Zacks Equity Research

Cardinal Health's (CAH) third-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.

Zacks Equity Research

Baxter (BAX) Q1 Earnings Beat Estimates, '24 EPS View Raised

by Zacks Equity Research

Baxter (BAX) reports better-than-expected first-quarter earnings and sales. BAX's quarterly results reflect solid demand for a range of its medically essential products.

Zacks Equity Research

BD (BDX) Q2 Earnings Surpass Estimates, FY24 View Revised

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in all segments and both geographic regions in the fiscal second quarter.

Zacks Equity Research

Accuray (ARAY) Q3 Earnings Lag Estimates, Gross Margin Contracts

by Zacks Equity Research

Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.

Zacks Equity Research

Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Glaukos' (GKOS) first-quarter 2024 results showcase growth in revenues while earnings miss the Zacks consensus Estimate. Loss at the operating level raises concern as well.

Zacks Equity Research

Here's Why You Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

STERIS' (STE) strong prospects in the healthcare and pharmaceutical industries bode well for investors.

Zacks Equity Research

Merit Medical (MMSI) Q1 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Merit Medical (MMSI) benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter.

Zacks Equity Research

CVS Health's (CVS) Q1 Earnings Miss Estimates, Margins Up

by Zacks Equity Research

CVS Health's (CVS) Q1 performance is impacted by a decline in the Health Services segment due to continued pharmacy client price improvements.

Zacks Equity Research

Inari Medical (NARI) Q1 Earnings Miss Estimates, OpEx Rises

by Zacks Equity Research

Inari Medical's (NARI) first-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the companies continue to incur operating losses.

Zacks Equity Research

IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed

by Zacks Equity Research

IDEXX (IDXX) delivers better-than-expected earnings in the first quarter of 2024.